diabetestalk.net

Soon Your Car Will Know When You Are Having A Heart Attack — And Know How To React

Soon your car will know when you are having a heart attack — and know how to react

Soon your car will know when you are having a heart attack — and know how to react

Car manufacturers constantly upgrade safety technology. In 1958, Saab was the first to make seat belts standard. In the early 1970s the Oldsmobile Toronado could be purchased with high-mounted brake lights and airbags. Now with rapid advances in wearables and autonomous driving systems, a new wave of safety technology is on the way — allowing cars to react to medical emergencies.
Toyota and Ford are each independently researching how to pair health sensors with autonomous driving technology so that vehicles will be able to pull off the road and call for help if they determine a passenger is having either cardiac trouble or a diabetic event.
Chuck Gulash, a senior executive engineer at Toyota and director of its Collaborative Safety Research Center in Ann Arbor, Michigan, said heart rate and blood glucose levels can be effectively monitored, as they are associated with a relatively high number of vehicle crashes.
He referenced a 2009 National Highway Traffic Safety Administration study, which found that diabetic events were behind 20 percent of crashes precipitated by driver-reported medical emergencies, and heart attacks accounted for an additional 11 percent. As people are not always aware they're having medical trouble, the actual figure could be higher.
"We've spent 30 years scientifically measuring crash criteria, but there wasn't a lot of research into physiological metrics," Gulash said.
Heart-related medical issues behind the wheel are extremely dangerous because the sufferer can lose consciousness, said Dr. Nitish Badhwar, professor of clinical medicine and direct Continue reading

Rate this article
Total 1 ratings
The 3 Best Diabetes Stocks to Buy in 2018

The 3 Best Diabetes Stocks to Buy in 2018

Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their bloodstream, which can lead to a wide range of health problems.
More than 30 million Americans already have diabetes, and another 84 million are at risk of developing the disease. Given these massive numbers, perhaps it isn't shocking to learn that diabetes costs the U.S. healthcare system more than $245 billion annually.
A market opportunity that large has attracted the attention of plenty of publicly traded companies:
Company
Market Cap
Products
Abbott Laboraties
$96 billion
Continuous glucose monitor
AstraZeneca
$84 billion
Pharmaceuticals
Becton, Dickinson
$48 billion
Diagnostic and delivery devices
Dexcom (NASDAQ:DXCM)
$3.8 billion
Continuous glucose monitor
Eli Lilly
$89 billion
Insulin and pharmaceuticals
Insulet (NASDAQ:PODD)
$3.3 billion
Insulin pump
Johnson & Johnson (NYSE:JNJ)
$381 billion
Glucose monitor and pharmaceuticals
Lexicon Pharmaceuticals
$1.1 billion
Pharmaceuticals
MannKind
$364 million
Inhaled insulin
Medtronic
$106 billion
Insulin pump and continuous glucose monitor
Novo Nordisk (NYSE:NVO)
$123 billion
Insulin and pharmaceuticals
Sanofi
$120 billion
Insulin and pharmaceuticals
Senseonics Holdings
$360 million
Continous glucose monitor
Data source: Yahoo! Finance. Market cap data as of 10/25/17.
But which of these diabetes stocks is the best bet for investors heading into 2018? Here are my three favorites.
A big competitor throws in the towel
Roughly 3 millio Continue reading

3 Top Diabetes Stocks to Buy Now

3 Top Diabetes Stocks to Buy Now

Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs associated with diabetes are projected to increase by more than 50% by 2030.
But where there's a problem, there's also an opportunity. Healthcare companies continue to develop innovative new approaches to treating and managing diabetes. This innovation in turn creates value for investors.
At least 15 publicly traded companies have current products addressing diabetes either on the market or in development. A few of these stocks hold the potential to generate market-beating returns for investors. I think that Abbott Laboratories (NYSE:ABT), Becton, Dickinson and Company (NYSE:BDX), and Johnson & Johnson (NYSE:JNJ) will especially stand out over the next few years. Here's why these are three top diabetes stocks to buy now.
Abbott Labs
Abbott Labs claims a market cap of close to $98 billion. The company's primary focus in the past has been on branded generic drugs, diagnostic systems and tests, nutritional products, and cardiovascular and neuromodulation medical devices. Abbott's diabetes care unit revenue wasn't even listed separately in the company's financial statements.
However, diabetes should be much more important to Abbott in the future. In September, the U.S. Food and Drug Administration (FDA) approved the company's FreeStyle Libre Flash Glucose Monitoring System. It's the first continuous glucose monitoring (CGM) system approved by the FDA that doesn't require a finger-stick blood sa Continue reading

The most innovative companies in diabetes

The most innovative companies in diabetes

Diabetes affects a startling number of people worldwide -- some 415 million in 2015, with 44.3 million of those in North America. About a third of people with diabetes do not know they have it.
Last year Quid kicked off a new series focusing on Type 2 diabetes (which accounts for nearly 95% of the world’s cases), including an analysis of 40,000 patient posts from a leading diabetes forum.
Still, we wanted to take a closer look at the disease, specifically at innovative companies treating diabetes.
First we looked in our proprietary company database of 50,000 startups to see which are receiving the largest VC investments and for what.
We identified more than 1,300 companies playing in the diabetes landscape. In the network above, 9.6% of companies focus on research and drug discovery, with a whopping $2.9 billion in investment in this area.
And even though it includes fewer companies and makes up a much smaller portion of the network, clinical trial-stage drug manufacturers pulled in the next-highest investment figure, roughly $2 billion in total since 2012. Next, companies in glucose monitoring, diagnostics, and immune-based therapies make up a significant portion of the network and account for a huge chunk of the funds raised.
One cluster was particularly interesting in this map: startups in the biotech, small molecules and drug delivery cluster account for just 2.7% of the network but pulled in relatively high investment dollars, topping $955 million.
Zooming in, we see that companies in this cluster produce very interesting technologies indeed.
Delpor, for example, man Continue reading

Time To Buy Medtronic? Watch Diabetes Segment Transformation

Time To Buy Medtronic? Watch Diabetes Segment Transformation

Summary
Medtronic is confident of filling the supply-demand gap in its diabetes franchise by end of FY 2018.
The company plans to launch next generation professional CGM device for type 2 diabetes patients in fiscal year 2018.
Partnerships with clinics and hospitals for diabetes management and prevention are expected to help Medtronic offer integrated care to patients.
The company has also entered intofavorable relationships with major payers in USA.
However, investors should be aware ofcertain business risks of the diabetes segment.
Medtronic (MDT) is one of the few medical device companies with product portfolio vastly diversified across therapeutic areas and geographies. The inversion deal with Ireland based Covidien has not only helped the company to shift to lower-tax base but has also vastly expanded the company’s geographic and therapeutic footprint. And then the recently concluded divestiture deal with Cardinal Health of non-core and low growth assets for a consideration of $6.1 billion has truly landed this company in an enviable spot.
Once Medtronic manages to put to rest the supply constraints it is facing in its diabetes business, I believe that the company can easily reach the 12-month consensus target price for Medtronic, of around $91.11.
The diabetes group currently contributes only about 6.3% to Medtronic’s total revenues. However, it is on a cusp of major transformation, one that is capable of lifting or dragging both investor sentiment as well as share price of this diversified medical device player. It should be noted that the lower-than-anticipated Continue reading

No more pages to load

Popular Articles

Related Articles